<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581214</url>
  </required_header>
  <id_info>
    <org_study_id>201805045</org_study_id>
    <nct_id>NCT03581214</nct_id>
  </id_info>
  <brief_title>Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate</brief_title>
  <acronym>O2P2</acronym>
  <official_title>Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 2/3 of laboring women receive supplemental oxygen (O2) in an attempt to reverse&#xD;
      perceived fetal hypoxia on electronic fetal monitoring (EFM). O2 supplementation is most&#xD;
      commonly used in patients with Category II EFM, a class of EFM patterns designed in part to&#xD;
      identify fetal acidemia. This liberal use of O2 in laboring patients is concerning because&#xD;
      hyperoxygenation in infants is associated with adverse outcomes including retinopathy and&#xD;
      abnormal neurodevelopment. Furthermore, excess O2 exposure is linked to free radical&#xD;
      generation and subsequent oxidative cell damage. This calls for a closer look at the safety&#xD;
      of intrauterine O2 exposure. The proposed project explores potential mechanisms for harm with&#xD;
      maternal O2 supplementation in laboring patients with Category II EFM. Specifically, this&#xD;
      project will determine the effect of O2, compared to room air (RA), on umbilical cord and&#xD;
      maternal levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), markers of free&#xD;
      radical-induced oxidative stress. The study will also explore the correlation between urinary&#xD;
      and blood markers of oxidative stress. Banked specimens will be used to investigate the&#xD;
      potential effect of peripartum O2 exposure on placental oxidative stress in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Umbilical artery malondialdehyde</measure>
    <time_frame>At delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Umbilical artery 4-hydroxynonenal</measure>
    <time_frame>At delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal malondialdehyde</measure>
    <time_frame>Within 1 hour of delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal 4-hydroxynonenal</measure>
    <time_frame>Within 1 hour of delivery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Intrauterine Resuscitation</condition>
  <arm_group>
    <arm_group_label>Room air</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Room air (no mask)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10L/min Oxygen by facemask</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No oxygen</intervention_name>
    <description>No facemask, room air only</description>
    <arm_group_label>Room air</arm_group_label>
    <other_name>Room air</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>10Liters/minute oxygen by facemask</description>
    <arm_group_label>Oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton&#xD;
&#xD;
          -  Gestational age â‰¥37 weeks&#xD;
&#xD;
          -  Spontaneous labor or induction of labor&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major fetal anomaly&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  Category III electronic fetal monitoring&#xD;
&#xD;
          -  Maternal hypoxia&#xD;
&#xD;
          -  Preeclampsia&#xD;
&#xD;
          -  Intrauterine growth restriction&#xD;
&#xD;
          -  Pregestational diabetes&#xD;
&#xD;
          -  Tobacco use&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study is in pregnant females only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nandini Raghuraman, MD MS</last_name>
    <phone>314 273 2939</phone>
    <email>nraghuraman@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandini Raghuraman, MD MS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Nandini Raghuraman</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

